Presenting Companies

Northstar Neuroscience, Inc. is a medical device company founded by an experienced management team committed to developing innovative medical technologies that restore function and quality of life for people suffering from neurological diseases and disorders. The company's technology platforms address neurological impairment and are based on an innovative dimension of the new and growing field of neurotechnology; the application of electrical therapies to treat diseases and disorders that affect the nervous system. The first platform involves investigational technologies that stimulate the cortex of the brain in an effort to promote the restoration of function for patients who have suffered a stroke. Recovery of function from stroke is associated with a series of well-documented neuroplastic changes in the motor cortex. Such changes allow uninjured areas of the cortex to assume some of the functional capabilities that were previously associated with areas damaged by stroke. These changes in the brain are thought to be related to an expansion of the neural network involved in control of the initiation and production of movement. This hypothesis is supported by both animal and clinical studies, which demonstrate a causal relationship between expansion of cortical motor function output and recovery. The therapy involves the implantation of an investigational device for the delivery of electrical stimulation to the area of the brain involved in recovery of function. This electrical stimulation is delivered using electrical parameters intended to facilitate the expansion of the neural network controlling limb function.

Restorative Therapies, Inc. was founded in response to the pioneering research of Dr. John McDonald.  His basic science research suggests that repetitive neural activity stimulates the central nervous system to become more functional and to promote nerve cell growth.  This activity based process (patent pending) is known as Restorative Therapy. Increasing activity levels can help to improve overall health, cardiovascular fitness and blood circulation, range of motion, and flexibility. It can also raise energy levels, improve balance, reduce spasticity, decrease muscle atrophy, and assist with the performance of activities of daily living. RTI designs and supplies Restorative Therapy medical devices to help people with a neurological impairment achieve their full recovery potential.

Andara Life Science Inc. is an Indianapolis-based biotechnology company that is
developing and commercializing a platform of promising therapeutic devices and drugs
for the treatment of central nervous system injury and disease.

GentCorp is a power source development company founded by Mr. Wilson Greatbatch to explore and overcome the technical limits of current implantable battery power technology. We develop and manufacture novel power source solutions to meet the expanding clinical needs of the implantable medical device industry.





Neuronetrix aims to diagnose neurological disorders during the earliest stages of the disease and before irreversible damage has occurred.  Often, this will be prior to the onset of noticeable symptoms. These disorders include those which affect young children such as dyslexia and autism as well as disorders of adulthood such as Alzheimer's, Parkinson's, or diabetic cognitive impairment. An early diagnosis with the COGNISION™ System will give patients and clinicians the best opportunity for effective intervention.



Medtrode Inc. is a medical device company developing a portfolio of next generation neurostimulation therapies that enable site-specific delivery of electrical stimulation used to treat neurological and other disorders. At the core of the delivery system is a novel, patented multi-functional DBS electrode (MCE) that is easier and safer to implant yet offers unprecedented therapy configuration. Matched with a true multichannel implantable pulse generator (IPG) under development, the total system is expected to be the only device on the market that will empower clinicians to record and reconfigure the electrical field, post-implantation. The reduced size of our MCE design and the ability to simultaneously record and stimulate with one device is anticipated to also permit additional therapies in DBS and other neurostimulation areas that are unachievable with current devices. In addition to our unique MCE technology, Medtrode is developing a new implantation approach with the objective to greatly streamline the surgical procedure for neurosurgeons.



The mission of NeuroNexus Technologies (N2T) is to become the leading supplier of implantable microscale probe systems for establishing chemical and electrical interfaces to the nervous system. N2T's proven multi-channel microelectrode technologies are the core of neural probe systems directed at providing cutting-edge solutions for treating neurological disorders and diseases, as well as pushing the envelope in the neuroscience research and drug discovery markets. N2T is focused on 'making the connection' to the brain.